News
IRWD
4.810
+2.78%
0.130
Weekly Report: what happened at IRWD last week (1102-1106)?
Weekly Report · 2d ago
Ironwood Pharmaceuticals, Inc. Just Beat EPS By 11%: Here's What Analysts Think Will Happen Next
Simply Wall St · 2d ago
Selling US$1.3m Of Ironwood Pharmaceuticals Stock Rewarded Insiders
Simply Wall St · 4d ago
Ironwood (IRWD) Q3 2026 Earnings Call Transcript
NASDAQ · 5d ago
What Ironwood Pharmaceuticals (IRWD) Said on Its Q3 Earnings Call
NASDAQ · 5d ago
Ironwood Q3 Net Income Rises 49%; Raises FY26 Revenue And EBITDA Outlook; Stock Up
NASDAQ · 5d ago
Ironwood Pharmaceuticals Q3 2026 Earnings Call Transcript
Benzinga · 5d ago
Ironwood reports Q3 EPS 36c, consensus 32c
TipRanks · 5d ago
Ironwood raises FY26 revenue view to $485M-$510M from $460M-$485M
TipRanks · 5d ago
*Ironwood Pharmaceuticals Raises 2026 View To Rev $485M-$510M >IRWD
Dow Jones · 6d ago
*Ironwood Pharmaceuticals 3Q Net $59.8M >IRWD
Dow Jones · 6d ago
*Ironwood Pharmaceuticals 3Q Rev $133M >IRWD
Dow Jones · 6d ago
Press Release: Ironwood Pharmaceuticals Raises Full-Year 2026 Financial Guidance Driven by Continued LINZESS U.S. Net Sales Growth and Strong Third Quarter Financial Performance
Dow Jones · 6d ago
*Ironwood Pharmaceuticals 3Q Adj EPS 36c >IRWD
Dow Jones · 6d ago
*Ironwood Pharmaceuticals 3Q EPS 36c >IRWD
Dow Jones · 6d ago
Press Release: Ironwood Pharmaceuticals Raises -2-
Dow Jones · 6d ago
Ironwood management to meet with Citizens
TipRanks · 6d ago
Ironwood Pharmaceuticals Q3 2026 Earnings Preview
Seeking Alpha · 6d ago
Weekly Report: what happened at IRWD last week (1026-1030)?
Weekly Report · 11/02 09:52
Ironwood Pharmaceuticals to Host Third Quarter 2026 Investor Update Call
Barchart · 10/28 15:05
More
Webull provides a variety of real-time IRWD stock news. You can receive the latest news about Ironwood through multiple platforms. This information may help you make smarter investment decisions.
About IRWD
Ironwood Pharmaceuticals, Inc. is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI), and rare diseases. It is focused on the development and commercialization of GI product opportunities in areas of significant unmet need. LINZESS (linaclotide), its commercial product, is indicated for adult men and women suffering from irritable bowel syndrome with constipation (IBS-C), or chronic idiopathic constipation (CIC), and for pediatric patients ages 6-17 years-old suffering from functional constipation (FC). Linaclotide is available under the trademarked name CONSTELLA to adult men and women suffering from IBS-C or CIC and pediatric patients. The Company is also engaged in advancing apraglutide, a synthetic long-acting peptide analog of glucagon-like peptide-2 (GLP-2), for short bowel syndrome (SBS), patients who are dependent on parenteral support.